• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

作者信息

Mai Elias K, Hielscher Thomas, Bertsch Uta, Schlenzka Jana, Salwender Hans J, Munder Markus, Gerecke Christian, Dührsen Ulrich, Brossart Peter, Neben Kai, Hillengass Jens, Raab Marc S, Merz Maximilian, Baertsch Marc-Andrea, Jauch Anna, Hose Dirk, Martin Hans, Lindemann Hans-Walter, Blau Igor W, Scheid Christof, Weisel Katja C, Goldschmidt Hartmut

机构信息

Department of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

出版信息

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29.

DOI:10.1038/s41375-018-0195-9
PMID:29959413
Abstract
摘要

相似文献

1
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.在新诊断的、适合移植的多发性骨髓瘤患者中，使用高剂量或低剂量地塞米松进行基于硼替佐米的诱导治疗。
Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29.
2
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.硼替佐米与地塞米松联用环磷酰胺或来那度胺治疗新诊断多发性骨髓瘤的疗效、医疗资源利用及成本
Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14.
3
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.硼替佐米-环磷酰胺-地塞米松（VCD）与硼替佐米-沙利度胺-地塞米松（VTD）方案作为新诊断的适合移植的多发性骨髓瘤患者诱导治疗的比较：一项荟萃分析
Br J Haematol. 2014 Sep;166(5):702-10. doi: 10.1111/bjh.12946. Epub 2014 May 26.
4
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.硼替佐米、环磷酰胺和地塞米松（VCD）与硼替佐米、多柔比星和地塞米松（PAd）在新诊断骨髓瘤中的 III 期临床试验。
Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.
5
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.维奈托克联合硼替佐米、地塞米松和达雷妥尤单抗治疗多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e339-e343. doi: 10.1016/j.clml.2018.06.003. Epub 2018 Jun 18.
6
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.硼替佐米联合沙利度胺和地塞米松与沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者双自体干细胞移植前诱导治疗和巩固治疗的比较：一项随机 3 期研究。
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
7
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.复发多发性骨髓瘤患者中卡非佐米与地塞米松联合用药对比硼替佐米与地塞米松联合用药：3期研究ENDEAVOR（NCT01568866）按年龄亚组划分的结果
Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17.
8
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.皮下注射与静脉注射硼替佐米用于新诊断多发性骨髓瘤的两种不同诱导治疗：前瞻性GMMG-MM5试验的中期分析
Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.
9
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.硼替佐米为基础与非硼替佐米为基础的诱导治疗在前未经治疗多发性骨髓瘤患者自体造血干细胞移植前：III 期随机对照试验的荟萃分析。
J Clin Oncol. 2013 Sep 10;31(26):3279-87. doi: 10.1200/JCO.2012.48.4626. Epub 2013 Jul 29.
10
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.含硼替佐米的方案（BCR）用于治疗不符合移植条件的多发性骨髓瘤。
Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

引用本文的文献

1
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.新诊断多发性骨髓瘤患者早期发病率和死亡率的预测因素：来自 3700 例患者的五项随机对照 III 期临床试验数据。
Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7.
2
Expression of NEAT1 can be used as a predictor for Dex resistance in multiple myeloma patients.NEAT1 的表达可作为多发性骨髓瘤患者对地塞米松耐药的预测因子。
BMC Cancer. 2023 Jul 5;23(1):630. doi: 10.1186/s12885-023-11084-x.
3
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
来那度胺对比硼替佐米用于多发性骨髓瘤一线自体干细胞移植后的维持治疗。
Blood Cancer J. 2021 Jan 7;11(1):1. doi: 10.1038/s41408-020-00390-3.
4
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者基于来那度胺的治疗的临床管理。
Ann Hematol. 2020 Aug;99(8):1709-1725. doi: 10.1007/s00277-020-04023-4. Epub 2020 Apr 16.
5
Commentary: Lico A causes ER stress and apoptosis via up-regulating miR-144-3p in human lung cancer cell line H292.评论：Lico A 通过上调人肺癌细胞系 H292 中的 miR-144-3p 引起内质网应激和细胞凋亡。
Biomed J. 2018 Dec;41(6):391-392. doi: 10.1016/j.bj.2018.11.002. Epub 2019 Jan 2.